Ultragenyx Wins First Sanfilippo Gene Therapy Approval at $3.95M

On 17 September, a Thursday, the Food and Drug Administration cleared Fayuvi, the first treatment ever approved for Sanfilippo syndrome type A. The agency acted two days ahead of its own action date. Ultragenyx set the price the same day: $3.95 million, once.

Families who had watched the disorder take their children's language, then their movement, then their lives registered a single word — approved. Shareholders read a second signal. The decision arrived eight days after a Phase 3 failure in a different rare disease erased roughly 44% of the company's market value in one session.

A disease that erases childhood

Sanfilippo syndrome type A has a clinical name few outside medicine use: mucopolysaccharidosis type IIIA, or MPS IIIA. A defect in the SGSH gene leaves patients unable to produce enough of an enzyme called sulfamidase. That enzyme breaks down heparan sulfate, a long sugar chain the body recycles continuously. When it cannot, the molecule accumulates inside cells. The damage concentrates in the central nervous system.

The disease follows a cruel arc. Children develop on schedule for the first few years. Then language fades. Cognition slips. Motor control follows. STAT News, reporting the approval, called Sanfilippo "childhood Alzheimer's" — a comparison that captures the trajectory better than any incidence figure. Median life expectancy is about 15 years.

The addressable population is small even by rare-disease standards. Estimates place MPS IIIA at 3,000 to 5,000 patients across the developed world. Until this month, care was entirely supportive: managing seizures, sleep disruption and infections while the underlying disease ran its course. No therapy had ever been approved to change the mechanism.

That history is the reason the approval carries weight beyond one company's pipeline. Rare-disease medicine has learned to distrust early enthusiasm. The field's most cited cautionary tale — a diagnostics company that promised a revolution from a single blood test and delivered nothing — still shapes how investors read first-in-disease claims. A gene therapy that reaches full FDA approval is not a press release about a platform. It is a product with a label, a price and a manufacturing line.

One infusion, and a liver to watch

Fayuvi, also known as UX111, is an AAV9-based gene therapy given as a single intravenous infusion. The vector carries a working copy of SGSH into cells, with the aim of restoring a durable source of the missing enzyme. One dose, one procedure, no repeat schedule.

The label is narrower than the mechanism's ambition. The FDA approved Fayuvi for pediatric patients with preserved neurodevelopmental function, covering the neurologic manifestations of the disease. That wording reflects what gene therapy for neurodegeneration can realistically do today: slow or halt progression before the damage becomes irreversible. It is not a treatment for children who have already lost ground.

The safety profile carries a specific obligation. Elevated liver enzymes — ALT, AST and GGT — appeared in clinical studies, a familiar pattern for systemic AAV therapy. Every patient receives corticosteroids before and after the infusion, and liver function is assessed first, including total bilirubin. The therapy belongs in qualified treatment centres with the staff to run that monitoring. The practical consequence is that Fayuvi is a procedure, not a prescription.

The regulatory path was not a straight line. The FDA accepted Ultragenyx's Biologics License Application for UX111 in February 2025, granting Priority Review with a decision date of August 2025. The application then ran into difficulty and had to be resubmitted. In April 2026 the agency accepted the resubmitted file and set a new action date of 19 September 2026. Approval arrived on 17 September, two days early — a rare piece of good scheduling for a company that had spent the year absorbing bad news.

The approval of Fayuvi reflects years of research from scientists and developers, as well as unwavering support from so many families and patient organizations in the face of a devastating, universally fatal disease with no treatment options.— Emil D. Kakkis, M.D., Ph.D., chief executive officer and president, Ultragenyx

The manufacturing bottleneck it had to clear

Approval was only half the milestone. Fayuvi is the first FDA-approved commercial gene therapy manufactured on Andelyn Biosciences' Curator AAV platform, at the company's Columbus, Ohio facility. Andelyn, a contract development and manufacturing organization, framed the clearance as proof that its process can carry a commercial product rather than trial-scale batches.

That matters because AAV manufacturing is the sector's chronic constraint. Full-dose systemic gene therapies demand enormous quantities of vector, and yield is the reason launches arrive slowly and expensively. A platform that clears FDA review at commercial scale lowers risk for every programme built on it. The company said commercial product is expected to ship to qualified treatment centres within 30 to 60 days, supported by its UltraCare access programme.

The scientific lineage sits a few hours from the factory. Researchers at Nationwide Children's Hospital's Abigail Wexner Research Institute, working in the Jerry R. Mendell Center for Gene Therapy, developed the approach. Kevin Flanigan led the first clinical trial of a systemic gene therapy for the disorder. Fayuvi is the fourth gene therapy from that institution to reach FDA approval — an unusual concentration of translational output for a single paediatric hospital.

As we wrote in September, moving these therapies from freezer to infusion suite remains one of the sector's least glamorous bottlenecks: the scheduling problem between scarce manufacturing slots and available treatment centres is still unsolved. That analysis remains a more useful lens on the next two quarters than any launch press release.

FAYUVI (UX111) — TRL 9/9
─────────────────────────────────────────────────────────────
  TRL 1–3        TRL 4–6        TRL 7–8        TRL 9
  🔬   ────   🧪   ────   🏭   ────   ✅ ◉ NOW
  Research       Pilot          Scale-up        Market
─────────────────────────────────────────────────────────────
[██████████] 100%  ·  FDA full approval granted 17 September 2026
Source: FDA / Ultragenyx IR, 2026

The $3.95 million question

Ultragenyx did not release a price when the approval broke. STAT News noted the omission. By the time the company filed its formal announcement, the number was public: $3.95 million for the one-time treatment. Reuters described it as one of the world's most expensive drugs. At that level, Fayuvi joins a small club of one-shot therapies where the price is a strategic choice as much as a cost-recovery calculation.

Run the optimistic arithmetic first. At 3,000 to 5,000 patients and $3.95 million each, the theoretical ceiling runs into the high tens of billions. Reality intrudes at every step. The label covers preserved neurodevelopment in the developed world, which cuts the pool. Diagnosis lags, and many children are identified only after irreversible progression. A median life expectancy of 15 years caps the number of patients who could ever be treated. Payers will scrutinise a seven-figure invoice against a standard of care that is cheap today, because it is mostly palliative.

That is the structural difficulty at the centre of the gene-therapy model. A one-time treatment has to be priced against a lifetime of avoided cost — effectively, the profit or loss on a single treated patient. In haemophilia or spinal muscular atrophy, the avoided cost is large and recurring, which makes the arithmetic tractable. In an ultra-rare neurodegenerative disease with supportive care, the comparison is harder to win.

The assets around the product soften the picture. The approval came with a Priority Review Voucher, a tradeable credit that can be sold to another developer and converted into cash. Fayuvi is the company's second gene therapy approval and its sixth FDA approval overall. In August the company won accelerated approval for Genglycos, the first treatment for glycogen storage disease type Ia. Crysvita, the long-standing revenue engine, still generates the cash that funds the pipeline, even as its eventual loss of exclusivity clouds the out-years.

Read together, the approval and the voucher point to a company buying time and optionality rather than a company transformed overnight. A first-in-disease label is the strongest card in rare-disease development. It does not convert automatically into volume.

The counterweight: Aspire and a 44% drop

Set the approval against the year Ultragenyx has actually had. On 2 September the company reported that Aspire, its Phase 3 trial of apazunersen (GTX-102) in Angelman syndrome, missed both its primary endpoint — change from baseline in the Bayley-4 cognitive raw score — and its key secondary endpoint, net response on the Multidomain Responder Index. There was no meaningful separation between treated and control groups. The safety profile matched earlier studies; the efficacy signal did not.

Shares fell 44.7% to $14.67 in premarket trading the next morning. The analyst reaction was swift and severe. Evercore ISI downgraded to In Line and cut its target to $16 from $34. Baird moved to Neutral with a $16 target, down from $40. JPMorgan went to Neutral and lowered its target to $36 from $80. William Blair stepped to Market Perform and removed the Angelman drug from its pipeline valuation, citing ongoing cash consumption and the longer-term risk to Crysvita. The company said it would evaluate the programme and pursue "significant expense reductions."

That context turns the Sanfilippo approval into something more complicated than a win. A first-in-disease asset with a $3.95 million price tag buys credibility and revenue optionality. It does not restore the pipeline value that disappeared in a single Wednesday-evening announcement.

The market it lands in

Fayuvi arrives at an uncomfortable moment for gene therapy as a business. The science has advanced faster than the commercial model. Approvals have accumulated; revenue has lagged. Each new one-time therapy reopens the same argument between manufacturers, who price against decades of avoided cost, and payers, who see a single large invoice in the current budget year.

The recent regulatory backdrop adds texture. The company's own first attempt at the Sanfilippo filing did not survive its original August 2025 decision date; the company had to resubmit before the agency would clear it. That delay is not unusual in a period when the FDA's approach to rare-disease evidence has tightened, with patient groups pressing the agency publicly over evidentiary standards. The approval of Fayuvi, and Denali Therapeutics' enzyme replacement therapy Avlayah for Hunter syndrome before it, suggests the door has not closed — but the bar sits higher than the sector's promotional material implies.

For an investor reading the event, the relevant question is not whether Fayuvi works, but how quickly it can be paid for. Gene therapies that change a disease's course earn their economics over years, while their costs land in the launch quarter. That mismatch is why the sector's public companies tend to trade on pipeline probability rather than realised revenue, and why a single Phase 3 failure can erase more value than three approvals create. The company's own year is the cleanest illustration available.

The Priority Review Voucher softens the launch-period risk. A sale of the credit would bring non-dilutive cash onto the balance sheet at a moment when the company has promised to cut spending. Whether the company keeps the voucher or sells it is a signal worth watching: a sale reads as discipline, a hold reads as confidence in the launch.

Scale-up timing is the swing factor. Andelyn's platform approval is a genuine milestone, but a validated process and a fully supplied market are different problems. The company's 30-to-60-day guidance is an intention, not a shipment record. Watch the first confirmed patient infusions, not the first press release about readiness.

None of this diminishes the scientific result. MPS IIIA had no approved therapy before 17 September. Children born with the disorder now have a treatment, if they are diagnosed early enough and can reach a qualified centre. The gap between that sentence and a functioning commercial product is where the investment case will be decided.

What to watch from here

The next two quarters will decide whether the Sanfilippo approval becomes a commercial event or stays a regulatory one. Four markers will carry the signal.

The broader question is what Fayuvi proves. If a first-in-disease gene therapy for a disease this small can be manufactured at scale and reimbursed at seven figures, the template holds for the next ultra-rare programme in line. If centres cannot onboard patients fast enough, or payers refuse the invoice, the approval will read as a scientific achievement that stalled at the commercial gate — a pattern the field has seen before, and one that investors should price before the launch numbers arrive.

Sources